References
1
Martin GJ, Friedlander AM. Bacillus anthracis (Anthrax) In: Mandell GL, Bennett JE, Dolin R, Blaser M (eds). Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier Saunders, 2015:2391-409.
2
Lucey DR: Anthrax. In: Goldman L, Schafer AI (eds). Goldman"s Cecil Medicine. 24th ed. Elsevier, Philadelphia: 2011:1837-40.
3
Brook I. The prophylaxis and treatment of anthrax. Int J Antimicrob Agents. 2002;20:320-5.
4
Ertek M. Current Situation of Anthrax in Turkey. ANKEM Derg. 2011;25(Suppl 2):88-91.
5
Marik EP, Taeb MA. SIRS, qSOFA and new sepsis definition, J Thorac Dis. 2017;9:943-5.
6
Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. J Infect Public Health. 2010;3:98-105.
7
Baykam N, Ergonul O, Ulu A, Eren S, Celikbas A, Eroglu M, Dokuzoguz B. Characteristics of cutaneous anthrax in Turkey. J Infect Dev Ctries. 2009;3:599-603.
8
Demirdag K, Ozden M, Saral Y, Kalkan A, Kilic SS, Özdarendeli A. Cutaneous anthrax in adults: a review of 25 cases in the eastern Anatolian region of Turkey. Infection. 2003;31:327-30.
9
Karahocagil MK, Akdeniz N, Akdeniz H, Çalka Ö, Karsen H, Bilici A, Bilgili SG, Evirgen Ö, Cutaneous anthrax in Eastern Turkey: a review of 85 cases. Clin Exp Dermatol. 2008;33:406-11.
10
Öğütlü A. Anthrax. Journal of Experimental and Clinical Medicine. 2012;29:155-62.